Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| EyePoint, Inc.EYPT · Entity 5702 | Director | June 23, 2024 | June 25, 2024 |
| Kalaris Therapeutics, Inc.KLRS · Entity 6805 | Director | June 03, 2026 | June 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
EyePoint, Inc.
Report date June 23, 2024 · Filed June 25, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,000 |
Reported balance
After 2024-06-23 transaction · row 1
1 source rowRow 1 · 2024-06-23 · Exercise / conversion · Acquired 2,000 · Balance 4,000 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 2,000 |
Reported balance
After 2024-06-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-06-23 · Exercise / conversion · Disposed 2,000 · Balance 2,000 F1: The restricted stock units vests in three ratable annual installments beginning June 23, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units vests in three ratable annual installments beginning June 23, 2023.
Kalaris Therapeutics, Inc.
Report date June 03, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.72 · Expires 2036-06-02 | Direct | 9,000 |
Reported balance
After 2026-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 9,000 · Balance 9,000 F1: The option was granted on June 3, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on June 3, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 03, 2026 Filed Jun 4, 2026 20:22 UTC | Kalaris Therapeutics, Inc. KLRS · Entity 6805 | GrantStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $4.72 | $0.00 |
DisclosureSEC source: 0001193125-26-257462 · ownership.xml · derivative · entry 1 ADAMIS ANTHONY P · CIK 0001277479 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2036-06-02 F1 · derivative.exercise_date: The option was granted on June 3, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service. Read SEC document |
| April 10, 2025 Filed Apr 11, 2025 20:52 UTC | Kalaris Therapeutics, Inc. KLRS · Entity 6805 | GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $7.31 | $0.00 |
DisclosureSEC source: 0000950170-25-053339 · ownership.xml · derivative · entry 1 ADAMIS ANTHONY P · CIK 0001277479 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2035-04-09 F1 · derivative.exercise_date: The option was granted on April 10, 2025. The shares underlying the option are scheduled to vest over three years in equal monthly installments from March 18, 2025 through March 18, 2028, subject to continuous service. Read SEC document |
| March 18, 2025 Filed Mar 18, 2025 21:37 UTC | Kalaris Therapeutics, Inc. KLRS · Entity 6805 | GrantStock Option (right to buy) · Derivative | 12,989 | Not disclosed Strike: $0.55 | Not disclosed |
DisclosureSEC source: 0000950170-25-041475 · ownership.xml · derivative · entry 2 ADAMIS ANTHONY P · CIK 0001277479 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,989 Underlying: Common Stock · 12,989 shares Expires 2032-07-25 F1 · date: Stock option assumed in connection with the closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of November 7, 2024 (the "Merger Agreement"), by and among the Issuer, Aurora Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Issuer, and Kalaris Tx, Inc. (previously named Kalaris Therapeutics, Inc.), a Delaware corporation ("KTx"), in exchange for an outstanding option to purchase shares of KTx pursuant to the terms and conditions of the Merger Agreement (such transaction, the "Merger"). F3 · price: Pursuant to the terms of the Merger Agreement, as the effective time of the Merger, each outstanding option to purchase shares of KTx common stock, whether or not vested, was converted into an option to acquire shares of common stock of the Issuer, with necessary adjustments to the number of shares and exercise price to reflect an exchange ratio equal to 0.2016 per share, on the same terms and conditions as were applicable immediately prior to the effective time of the Merger. F2 · derivative.exercise_date: This option vests over four years beginning on the vesting commencement date of October 1, 2021, with 25% of the shares underlying the option having vested on October 1, 2022, and an additional 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter. Read SEC document |
| March 18, 2025 Filed Mar 18, 2025 21:37 UTC | Kalaris Therapeutics, Inc. KLRS · Entity 6805 | GrantStock Option (right to buy) · Derivative | 19,484 | Not disclosed Strike: $0.55 | Not disclosed |
DisclosureSEC source: 0000950170-25-041475 · ownership.xml · derivative · entry 1 ADAMIS ANTHONY P · CIK 0001277479 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,484 Underlying: Common Stock · 19,484 shares Expires 2032-07-25 F1 · date: Stock option assumed in connection with the closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of November 7, 2024 (the "Merger Agreement"), by and among the Issuer, Aurora Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Issuer, and Kalaris Tx, Inc. (previously named Kalaris Therapeutics, Inc.), a Delaware corporation ("KTx"), in exchange for an outstanding option to purchase shares of KTx pursuant to the terms and conditions of the Merger Agreement (such transaction, the "Merger"). F3 · price: Pursuant to the terms of the Merger Agreement, as the effective time of the Merger, each outstanding option to purchase shares of KTx common stock, whether or not vested, was converted into an option to acquire shares of common stock of the Issuer, with necessary adjustments to the number of shares and exercise price to reflect an exchange ratio equal to 0.2016 per share, on the same terms and conditions as were applicable immediately prior to the effective time of the Merger. F2 · derivative.exercise_date: This option vests over four years beginning on the vesting commencement date of October 1, 2021, with 25% of the shares underlying the option having vested on October 1, 2022, and an additional 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter. Read SEC document |
| June 23, 2024 Filed Jun 25, 2024 20:16 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionRestricted Stock Units · Derivative | 2,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-005299 · primarydocument.xml · derivative · entry 2 ADAMIS ANTHONY P · CIK 0001277479 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock units vests in three ratable annual installments beginning June 23, 2023. F1 · derivative.expiration_date: The restricted stock units vests in three ratable annual installments beginning June 23, 2023. Read SEC document |
| June 23, 2024 Filed Jun 25, 2024 20:16 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-005299 · primarydocument.xml · nonDerivative · entry 1 ADAMIS ANTHONY P · CIK 0001277479 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 05, 2024 Filed Jan 10, 2024 01:53 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantStock Option (Right to Buy) · Derivative | 25,014 | $0.00 Strike: $20.40 | $0.00 |
DisclosureSEC source: 0001562180-24-000391 · primarydocument.xml · derivative · entry 1 ADAMIS ANTHONY P · CIK 0001277479 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,014 Underlying: Common Stock · 25,014 shares Expires 2034-01-04 Read SEC document |
| June 23, 2023 Filed Jun 26, 2023 21:10 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionRestricted Stock Units · Derivative | 2,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-005502 · primarydocument.xml · derivative · entry 2 ADAMIS ANTHONY P · CIK 0001277479 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock units will vest in three equal annual installments beginning June 23, 2023. F1 · derivative.expiration_date: The restricted stock units will vest in three equal annual installments beginning June 23, 2023. Read SEC document |
| June 23, 2023 Filed Jun 26, 2023 21:10 UTC | EyePoint, Inc. EYPT · Entity 5702 | Exercise / conversionCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-005502 · primarydocument.xml · nonDerivative · entry 1 ADAMIS ANTHONY P · CIK 0001277479 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 20, 2023 Filed Jun 22, 2023 13:18 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantStock Option (Right to Buy) · Derivative | 13,000 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001562180-23-005447 · primarydocument.xml · derivative · entry 2 ADAMIS ANTHONY P · CIK 0001277479 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2033-06-19 Read SEC document |
| June 20, 2023 Filed Jun 22, 2023 13:18 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantStock Option (Right to Buy) · Derivative | 26,100 | $0.00 Strike: $3.26 | $0.00 |
DisclosureSEC source: 0001562180-23-005447 · primarydocument.xml · derivative · entry 1 ADAMIS ANTHONY P · CIK 0001277479 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,100 Underlying: Common Stock · 26,100 shares Expires 2033-06-19 Read SEC document |
| June 23, 2022 Filed Jun 27, 2022 20:38 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $7.54 | $0.00 |
DisclosureSEC source: 0001562180-22-005368 · primarydocument.xml · derivative · entry 2 ADAMIS ANTHONY P · CIK 0001277479 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2032-06-23 F2 · derivative.exercise_date: The option becomes exercisable in three ratable annual installments beginning on June 23, 2023. Read SEC document |
| June 23, 2022 Filed Jun 27, 2022 20:38 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantRestricted Stock Units · Derivative | 6,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-005368 · primarydocument.xml · derivative · entry 1 ADAMIS ANTHONY P · CIK 0001277479 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires not disclosed F1 · derivative.exercise_date: The restricted stock units will vest in three equal annual installments beginning June 23, 2023. F1 · derivative.expiration_date: The restricted stock units will vest in three equal annual installments beginning June 23, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.